Systematic review: Anti-viral therapy of recurrent hepatitis C after liver transplantation

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 2, 2011, Pages 163-174

  Guillouche, P ^a   Feray C ^a  

^a HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BOCEPREVIR; CYCLOSPORIN A; INTERFERON; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TACROLIMUS; TELAPREVIR; VIRUS RNA;

ANEMIA; ANTIVIRAL THERAPY; ASTHENIA; CLINICAL TRIAL; CYTOPENIA; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY INTERVENTION; FATIGUE; FLU LIKE SYNDROME; GENETIC POLYMORPHISM; GENOME ANALYSIS; GRAFT SURVIVAL; HEMOLYTIC ANEMIA; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPLAKIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MEDLINE; MENTAL DISEASE; MIXED INFECTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT VIRUS INFECTION; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; TREATMENT OUTCOME;

EID: 78650291306     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04505.x     Document Type: Review

References (92)

1. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
2. Feray C, Samuel D, Thiers V, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89: 1361-5.
3. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317-22.
4. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-6.
5. Berenguer M,. Natural history of recurrent hepatitis C. Liver Transpl 2002; 10 (Suppl. 1): S14-8.
6. Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-65.
7. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-77.
8. Feray C, Gigou M, Samuel D, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 1137-43. (Pubitemid 24323557)
9. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-20.
10. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-84.
11. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10.
12. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117: 619-25.
13. Watt KD, Lyden ER, Gulizia JM, McCashland TM,. Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome. Liver Transpl 2006; 12: 134-9.
14. Rosen HR, Shackleton CR, Higa L, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453-7.
15. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-17.
16. Berenguer M, Lopez-Labrador FX, Wright TL,. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666-78.
17. Rifai K, Sebagh M, Karam V, et al. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004; 41: 446-53.
18. Waki K,. UNOS Liver Registry: ten year survivals. Clin Transpl 2006: 29-39.
19. Gringeri E, Vitale A, Brolese A, et al. Hepatitis C virus-related cirrhosis as a significant mortality factor in intention-to-treat analysis in liver transplantation. Transplant Proc 2007; 39: 1901-3.
20. Berenguer M, Prieto M, Palau A, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003; 9: 228-35.
21. Carmiel-Haggai M, Fiel MI, Gaddipati HC, et al. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl 2005; 11: 1567-73.
22. Ercolani G, Grazi GL, Ravaioli M, et al. Histological recurrent hepatitis C after liver transplantation: outcome and role of retransplantation. Liver Transpl 2006; 12: 1104-11.
23. Yoo HY, Maheshwari A, Thuluvath PJ,. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl 2003; 9: 897-904.
24. Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM,. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl 2005; 11: 434-40.
25. Ghabril M, Dickson RC, Machicao VI, et al. Liver retransplantation of patients with hepatitis C infection is associated with acceptable patient and graft survival. Liver Transpl 2007; 13: 1717-27.
26. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-84.
27. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-97.
28. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-12.
29. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-62.
30. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-96.
31. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-7.
32. Mazzaferro V, Tagger A, Schiavo M, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 2: 1355-7.
33. Singh N, Gayowski T, Wannstedt CF, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65: 82-6.
34. Sheiner PA, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-8.
35. Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-98.
36. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-24.
37. Charlton MR, Bzowej N, Rossi S, Nelson DR,. Prophylactic peginterferon alfa-2a/ribavirin vs no prophylaxis following orthoptic liver transplantation for hepatitis C: 24 weeks virologic and safety responses. Hepatology 2007; 465 (Suppl.): 244A.
38. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-56.
39. Kizilisik TA, Al-Sebayel M, Hammad A, Al-Traif I, Ramirez CG, Abdulla A,. Hepatitis C recurrence in liver transplant recipients. Transplant Proc 1997; 29: 2875-7.
40. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27: 1403-7.
41. Ghalib R, Pandula R, Kadhim T, Clark C, Ankoma-Sey V, Fouzia S,. Treatment of recurrent hepatitis C after liver transplantation with alpha-2B interferon plus ribavirin. Hepatology 2000; 2: 291A.
42. Cotler SJ, Ganger DR, Kaur S, et al. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients. Transplantation 2001; 71: 261-6.
43. Samuel D, Bizollon T, Feray C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642-50.
44. Angelico M, Petrolati A, Lionetti R, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007; 46: 1009-17.
45. Shakil AO, McGuire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36: 1253-8.
46. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 1000-6.
47. Mukherjee S, Rogge J, Weaver L, Schafer DF,. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35: 3042-4. (Pubitemid 38102126)
48. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77: 190-4.
49. Dumortier J, Scoazec JY, Chevallier P, Boillot O,. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-74.
50. Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53-9.
51. Fernandez I, Meneu JC, Colina F, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805-12.
52. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6: 2348-55.
53. Balbi E, Leal CR, Pacheco-Moreira LF, et al. Treatment for recurrent hepatitis C virus infection after liver transplantation. Transplant Proc 2009; 41: 891-4.
54. Bizollon T, Pradat P, Mabrut JY, et al. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5: 1909-13.
55. Lilly L,. Improved survival in liver transplant recipients (LT) treated for recurrent hepatitis C (HCV) is seen in both relapsers and in sustained responders. 2008 American Transplant Congress. Toronto, Canada, May 2008.
56. Hanouneh I, Miller C, Aucejo F, Lopez R,. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008; 14: 53-8.
57. Sharma P, Marrero JA, Fontana RJ, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 1100-8.
58. Calmus Y,. Multicenter randomized trial in HCV- infected patients treated with peginterferon alfa-2a and ribavirin followed by ribavirin alone after liver transplantation: final report. 2008 American Transplant Congress. Toronto, Canada, May 2008.
59. Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008; 14: 512-25.
60. Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes. Transpl Int 2009; 22: 892-905.
61. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K,. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38: 1282-8.
62. Mueller AR, Platz KP, Blumhardt G, et al. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506? Clin Transplant 1995; 1: 176-84.
63. Zervos XA, Weppler D, Fragulidis GP, et al. Comparison of tacrolimus with neoral as primary immunosuppression in hepatitis C patients after liver transplantation. Transplant Proc 1998; 30: 1405-6. (Pubitemid 28309620)
64. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10: 1258-62.
65. Berenguer M, Aguilera V, Prieto M, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006; 12: 762-7.
66. Berenguer M, Royuela A, Zamora J,. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007; 13: 21-9.
67. Bizollon T, Ahmed SN, Radenne S, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283-7.
68. Rayhill SC, Barbeito R, Katz D, et al. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. Transplant Proc 2006; 38: 3625-8.
69. Cescon MGG, Cucchetti A, Ravaioli M,. Viral genotype, immunosuppressio with cyclosporine and donor age predict sustained viro logical response after antiviral treatment for hepatitis recurrence following liver transplantation. 2008 American Transplant Congress. Toronto, Canada, May 2008.
70. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ,. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8: 40-6.
71. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR,. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005; 11: 750-9.
72. Radecke K, Fruhauf NR, Miller M, et al. Outcome after orthotopic liver transplantation in five HIV-infected patients with virus hepatitis-induced cirrhosis. Liver Int 2005; 25: 101-8.
73. De Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983-93.
74. Wojcik KVM, Voigt E, Speidel N, et al. Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort. AIDS 2007; 21: 1363-5.
75. Tateo M, Roque-Afonso AM, Antonini TM, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009; 23: 1069-76.
76. Castells L, Esteban JI, Bilbao I, et al. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antivir Ther 2006; 11: 1061-70. (Pubitemid 44955182)
77. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
78. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-50.
79. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-16.
80. Gane EJRS, Stedman CA, et al. Abstract AASLD. Hepatology 2009; 50: 394A-5A.
81. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
82. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peginterferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 821-7.
83. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994; 91: 7792-6.
84. Law M, Maruyama T, Lewis J, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008; 14: 25-7.
85. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-6.
86. Fournier C, Duverlie G, Francois C, et al. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. Virol J 2007; 4: 35.
87. Castelain S, Schnuriger A, Francois C, et al. Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus. J Infect Dis 2008; 198: 332-5.
88. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 1996; 93: 15394-9. (Pubitemid 27009611)
89. Feray C, Gigou M, Samuel D, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998; 128: 810-6.
90. Vanwolleghem T, Bukh J, Meuleman P, et al. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology 2008; 47: 1846-55.
91. Davis GL, Nelson DR, Terrault N, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005; 11: 941-9.
92. Fofana I, Krieger SE, Grunert F, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010; 139: 953-64.